TrialArthritis research & therapy2007

A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab.

Hubert Marotte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.